Strong demand for AIDS and immune drugs, GSK raises full-year performance guidance
I'm PortAI, I can summarize articles.
GSK raised its full-year profit and sales expectations due to increased demand for HIV and immunology drugs. Q3 revenue reached £8.55 billion, a year-on-year increase of 4.9%, exceeding expectations by £300 million; earnings per share grew by 11% to £0.55, while analysts had expected £0.47. Full-year earnings per share are expected to grow by up to 12%, with revenue growth of up to 7%. Chief Commercial Officer Luke Mills will take over as CEO in January, facing sales challenges for the new drug pipeline
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments